Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

BackgroundSecukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical pract...

Full description

Bibliographic Details
Main Authors: Francisca Sivera, Victoria Núñez-Monje, Cristina Campos-Fernández, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Juan Miguel López-Gómez, Carolina Peña-González, Isabel de la Morena, Diego Bedoya-Sanchís, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martínez-Cristóbal, Francisco Javier Navarro-Blasco, José Miguel Senabre-Gallego, Juan José Alegre-Sancho
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Medicine
Subjects:
secukinumab
effectiveness
axial spondyloarthritis
non-radiographic axial spondyloarthritis
ankylosing spondylitis
real-world evidence
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1156557/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1156557/full

Similar Items